Reply Considerations for Drug Development for Heart Failure by Greene, Stephen J. & Gheorghiade, Mihai
J A C C V O L . 6 5 , N O . 1 0 , 2 0 1 5 Letters
M A R C H 1 7 , 2 0 1 5 : 1 0 5 7 – 6 3
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generalizability of the new therapy to a greater
extent.
In our zeal to maximize the likelihood that the study is
successful, we should not lose sight of the possibility
that the more selective the study population, the nar-
rower the scope of the application of the newer
intervention.
It may be that it is still appropriate to continue to
search for newer therapies that have wider applica-
tion (3) with more emphasis on effective utilization
of various biomarkers to maximally identify best
responders.*Jalal K. Ghali, MD
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We fully agree that narrow inclusion and exclusion
criteria within clinical trials limit generalizability of
study results to a smaller segment of the overall
population. However, heart failure (HF) is a clinical
syndrome and not a speciﬁc disease, representing a
ﬁnal common pathway for various admixtures of
cardiac and noncardiac abnormalities. This hetero-
geneity applies to chronic HF with reduced ejection
fraction, but is especially true for HF with preserved
ejection fraction (1) and hospitalized HF (HHF) pop-
ulations where randomized trials have consistently
failed to improve long-term patient outcomes (2).
Testing new molecules in HHF without the
rigorous early phase testing we suggest does not
preclude a subsequent positive trial result. However,
on the basis of past HHF trial experiences and
increasing understanding of the diversity in pre-
cipitants, amplifying factors, and cardiac substrates
among HHF patients, this approach fails to maximizethe chances of achieving a successful study result.
The traditional strategy has also proven expensive,
both in terms of direct ﬁnancial costs and opportunity
costs of investing several years for completion of
trials with lower probability of showing clinical
beneﬁt (3). Moreover, using heterogeneous pop-
ulations to test suboptimally understood therapies
increases the risk for any of 3 potential problematic
scenarios: 1) overall primary endpoint is met but a
segment of the study population derives no beneﬁt or
harm; 2) overall primary endpoint is not met, effec-
tively “killing” further drug development, but a
bidirectional drug effect exists whereby speciﬁc sub-
groups derive offsetting beneﬁt (i.e., a potentially
useful therapy is abandoned) and harm (4); and 3)
overall primary endpoint is met, but size of the effect
is small and despite regulatory approval, the therapy
is not widely accepted by payers.
We recognize the potential for discordance be-
tween efﬁcacy and “real world” clinical effectiveness
of therapies within medicine. We also appreciate the
differences in patient characteristics between HHF
clinical trials and registries (5). However, the “1 size
ﬁts all” approach to HHF drug development has
thus far failed to be productive (2). Rather, we favor
identifying the “disease” within HHF and targeting
the speciﬁc abnormality or process. A pragmatic
approach going forward would involve proving clear
clinical beneﬁt with a therapy in select HHF patients.
Subsequently, the therapy could be serially trialed in
additional patient subgroups for which sound bio-
logic plausibility may exist. Such an approach could
theoretically widen the application of the novel
therapy while, at minimum, provide a treatment
capable of helping an HHF patient subset. With over 1
million primary hospitalizations for HF annually in
the United States alone, improving outcomes for even
a segment of this population could yield enormous
public health beneﬁts.Stephen J. Greene, MD
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Circulatory Support
The Problem of the UninsuredWe read with interest the recent report by Stretch
et al. (1) regarding the increase in the use of short-
term mechanical circulatory support (MCS) in the
United States. The investigators demonstrated that
the increased use of MCS has occurred together with
improved in-hospital survival and decreased hospital
costs. Both aspects will need to demonstrate favor-
able trends for MCS to continue to gain widespread
acceptance for the treatment of cardiogenic shock.
The ﬁnancial implication of short-term MCS is the
topic we would like to discuss further.
An important question is whether health insurance
is a necessary prerequisite for MCS options. Accord-
ing to the investigators, 8.8% of MCS patients
between 2004 and 2007 and 6.7% between 2008 and
2011 were characterized as having “self-pay, no
charge, or other” as the primary payer. It is certainly
likely that the majority of these patients were unin-
sured. Furthermore, <10% of patients had Medicaid
as their primary insurance. There are no deﬁnitive
data on whether insurance status, or lack thereof, is a
determining factor in patients’ receiving appropriate
MCS therapy. Insurance status has been shown to
contribute to whether patients receive appropriate
medical therapy or percutaneous coronary interven-
tion for coronary artery disease and ST-segment
elevation myocardial infraction (2,3). Given the
much greater expense for MCS, it stands to reason
that ﬁnancial implications do have some role indetermining whether MCS is offered for patients in
cardiogenic shock. Although the investigators re-
ported that uninsured and Medicaid patients received
MCS therapy, it is unknown whether the percent of
patients in these categories is representative of the
entire cardiogenic shock population. Are uninsured
patients who require MCS being referred to and
accepted at centers that can perform this therapy?
The policy of individual MCS programs regarding
the uninsured is unknown. A recent survey of heart
transplantation programs revealed that 84% of pro-
grams required health insurance to actively list a
patient for transplantation (4). Whether the same is
true to consider short- or long-term MCS options is
unknown, but possibly very similar.
The decision to initiate short-term MCS may be just
one step in a pathway leading to long-term MCS and
possibly heart transplantation. The investigators
reported that 25% of patients who underwent short-
term MCS for heart failure indications eventually
underwent placement of permanent long-term de-
vices. Once patients have been stabilized with short-
term MCS devices, it can be difﬁcult to withhold
further treatment. Given the potential ﬁnancial im-
plications involved, it is not surprising that insurance
considerations will factor in the decision-making
process for hospitals to determine who is a candi-
date for short-term MCS. It remains to be seen if
the Patient Protection and Affordable Care Act will
change this dynamic by lowering the overall number
of uninsured patients. However, uninsured patients
in cardiogenic shock do not have time to wait for in-
surance to be obtained before deﬁnitive therapy is
needed. We recently published data showing that at
our institution, uninsured patients could undergo
placement of permanent MCS devices with successful
outcomes and subsequent attainment of health
insurance (5). Several of our patients were on short-
term MCS devices initially. Nonetheless, there is no
easy solution to the problem of uninsured patients in
cardiogenic shock. The ethics of withholding MCS to
uninsured patients in cardiogenic shock must be
vigorously debated in the United States, particularly
as MCS becomes more widespread and outcomes
continue to improve. A frank discussion of the
ﬁnancial implications both for patients and for the
health care system needs to be undertaken.*Navin Rajagopalan, MD
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